

REGENXBIO Inc.
Form 4
May 17, 2016

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
FMR LLC

(Last) (First) (Middle)
245 SUMMER STREET
(Street)

BOSTON, MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
REGENXBIO Inc. [RGNX]

3. Date of Earliest Transaction
(Month/Day/Year)
05/13/2016

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

___ Director ___X___ 10% Owner
___ Officer (give title below) ___X___ Other (specify below)
See Remark 1

6. Individual or Joint/Group Filing(Check Applicable Line)
X Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) | | | |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|---------|---|------------------|
| | | | Code | V | Amount | (A) or (D) | Price | | | |
| Common Stock | 05/13/2016 | | S | | 4,100 | D | \$ 11.25 (2) | 649,606 | I | See footnote (1) |
| Common Stock | 05/13/2016 | | S | | 900 | D | \$ 11.26 (3) | 648,706 | I | See footnote (1) |
| Common Stock | 05/13/2016 | | S | | 200 | D | \$ 11.26 (4) | 648,506 | I | See footnote (1) |
| Common Stock | 05/13/2016 | | S | | 101 | D | \$ 11.28 | 648,405 | I | See footnote |

Edgar Filing: REGENXBIO Inc. - Form 4

| | | | | | | | | |
|--------------|------------|---|-------|---|------------------|---------|---|-------------------------|
| Common Stock | 05/13/2016 | S | 100 | D | \$ 11.25 | 648,305 | I | (1) See footnote (1) |
| Common Stock | 05/13/2016 | S | 100 | D | \$ 11.29 | 648,205 | I | (1) See footnote (1) |
| Common Stock | 05/13/2016 | S | 29 | D | \$ 11.28 | 648,176 | I | (1) See footnote (1) |
| Common Stock | 05/16/2016 | S | 300 | D | \$ 12.11 (5) | 647,876 | I | (1) See footnote (1) |
| Common Stock | 05/16/2016 | S | 3,089 | D | \$ 11.79 (6) | 644,787 | I | (1) See footnote (1) |
| Common Stock | 05/16/2016 | S | 900 | D | \$ 11.91 (7) | 643,887 | I | (1) See footnote (1) |
| Common Stock | 05/16/2016 | S | 600 | D | \$ 12.12 (8) | 643,287 | I | (1) See footnote (1) |
| Common Stock | 05/16/2016 | S | 400 | D | \$ 11.87 (9) | 642,887 | I | (1) See footnote (1) |
| Common Stock | 05/16/2016 | S | 2,800 | D | \$ 11.69 (10) | 640,087 | I | (1) See footnote (1) |
| Common Stock | 05/16/2016 | S | 300 | D | \$ 12.12 (11) | 639,787 | I | (1) See footnote (1) |
| Common Stock | 05/16/2016 | S | 2,111 | D | \$ 12.02 (12) | 637,676 | I | (1) See footnote (1) |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: REGENXBIO Inc. - Form 4

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Owned Following Reporting Transaction (Instr. 6) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|---|
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|---|

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|---------|--------------|
| | Director | 10% Owner | Officer | Other |
| FMR LLC 245 SUMMER STREET BOSTON, MA 02210 | | X | | See Remark 1 |

Signatures

Marc R. Bryant, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson 05/17/2016

__Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) By F-Prime Capital Partners Healthcare Fund III LP, Impresa Fund III Limited Partnership and F-Prime Inc. The general partner of F-Prime Capital Partners Healthcare Fund III LP is F-Prime Capital Partners Healthcare Advisors Fund III LP (FPCPHA). FPCPHA and Impresa Fund III Limited Partnership are each solely managed by Impresa Management LLC, their general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. F-Prime Inc. is a wholly-owned subsidiary of FMR LLC.
- (2) The price reported for this transaction is the weighted average price of multiple trades at prices ranging from \$11.23 to \$11.29. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- (3) The price reported for this transaction is the weighted average price of multiple trades at prices ranging from \$11.26 to \$11.27. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- (4) The price reported for this transaction is the weighted average price of multiple trades at prices ranging from \$11.25 to \$11.27. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- (5) The price reported for this transaction is the weighted average price of multiple trades at prices ranging from \$12.09 to \$12.13. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- (6)

Edgar Filing: REGENXBIO Inc. - Form 4

The price reported for this transaction is the weighted average price of multiple trades at prices ranging from \$11.40 to \$12.11. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

(7) The price reported for this transaction is the weighted average price of multiple trades at prices ranging from \$11.60 to \$12.26. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

(8) The price reported for this transaction is the weighted average price of multiple trades at prices ranging from \$12.12 to \$12.14. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

(9) The price reported for this transaction is the weighted average price of multiple trades at prices ranging from \$11.64 to \$12.11. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

(10) The price reported for this transaction is the weighted average price of multiple trades at prices ranging from \$11.61 to \$12.13. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

(11) The price reported for this transaction is the weighted average price of multiple trades at prices ranging from \$12.12 to \$12.13. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

(12) The price reported for this transaction is the weighted average price of multiple trades at prices ranging from \$11.60 to \$12.26. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

Remark 1: Abigail P. Johnson is a Director, the Vice Chairman, the Chief Executive Officer and the President of FMR LLC. M

Remark 2: FMR Co., Inc. (FMRC), an indirect wholly-owned subsidiary of FMR LLC and an investment adviser registered un

Remark 3: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.